Crescent Biopharma (CBIO) Assets (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Assets data on file, last reported at $199.1 million in Q1 2026.

• Quarterly Assets rose 3223.16% year-over-year to $199.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $199.1 million (up 3223.16% YoY) and the FY2025 annual result came in at $240.3 million, up 574.66% from the prior year.
• Assets declined to $199.1 million in Q1 2026 per CBIO's latest filing, from $240.3 million in the prior quarter.
• Across five years, Assets topped out at $240.3 million in Q4 2025 and bottomed at $6.0 million in Q1 2025.
• The 5-year median for Assets is $56.0 million (2022), against an average of $78.5 million.
• The widest annual swing landed in 2025, when Assets tumbled 82.48%; it then jumped 3223.16% in 2026.
• Tracing CBIO's Assets over 5 years: stood at $51.8 million in 2022, then retreated by 12.53% to $45.3 million in 2023, then dropped by 21.4% to $35.6 million in 2024, then soared by 574.66% to $240.3 million in 2025, then decreased by 17.13% to $199.1 million in 2026.
• Per Business Quant, the three latest CBIO Assets figures stand at $199.1 million (Q1 2026), $240.3 million (Q4 2025), and $138.3 million (Q3 2025).

Peer Comparison